Empagliflozin and Major Renal Outcomes in Heart Failure

Autores da FMUP

• João Pedro Melo Marques Pinho Ferreira

  Autor

Participantes de fora da FMUP

• Packer, M
• Butler, J
• Zannad, F
• Pocock, SJ
• Filippatos, G
• Brueckmann, M
• Jamal, W
• Zeller, C
• Wanner, C
• Anker, SD
• EMPEROR Study Grp

Unidades de investigação

• Cirurgia e Fisiologia

• Laboratório Associado RISE- Rede de Investigação em Saúde

  

  Investigador

  Fernando Carlos De Landér Schmitt

Abstract

Empagliflozin and Renal Outcomes in Heart Failure In a planned pooled analysis of two trials that evaluated empagliflozin in patients with heart failure, major adverse renal outcomes occurred in 2.8% of the patients who received empagliflozin and in 3.5% of those who received placebo. Results differed between the two trials.

Keywords

• Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glomerular Filtration Rate; Glucosides; Heart Failure; Hospitalization; Humans; Kidney Diseases; Renal Replacement Therapy; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; empagliflozin; benzhydryl derivative; empagliflozin; glucoside; clinical outcome; clinical protocol; confidence interval; estimated glomerular filtration rate; follow up; hazard ratio; heart ejection fraction; heart failure; human; kidney disease; Letter; non insulin dependent diabetes mellitus; prospective study; randomized controlled trial (topic); renal replacement therapy; statistical analysis; administration and dosage; adverse event; complication; controlled study; drug effect; glomerulus filtration rate; heart failure; heart stroke volume; hospitalization; kidney disease; pathophysiology; randomized controlled trial; renal replacement therapy